HONZ PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.82 CNY | -4.74% |
|
+3.21% | -17.89% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,700 | 2,367 | 2,529 | 3,906 | 2,799 | 2,642 |
| Enterprise Value (EV) 1 | 2,548 | 2,420 | 2,918 | 4,240 | 3,112 | 2,999 |
| P/E ratio | 202 x | -89.5 x | 270 x | 356 x | -14.9 x | 229 x |
| Yield | 2.5% | - | 0.36% | - | - | - |
| Capitalization / Revenue | 3.06 x | 2.35 x | 2.74 x | 4.67 x | 5.22 x | 3.57 x |
| EV / Revenue | 2.89 x | 2.4 x | 3.17 x | 5.07 x | 5.81 x | 4.05 x |
| EV / EBITDA | 28 x | 37.8 x | 25.1 x | 130 x | -32.1 x | 20.8 x |
| EV / FCF | -14.4 x | 11.3 x | -8.44 x | -17.9 x | -166 x | -22.9 x |
| FCF Yield | -6.97% | 8.87% | -11.9% | -5.59% | -0.6% | -4.36% |
| Price to Book | 1.75 x | 1.58 x | 1.68 x | 2.6 x | 2.13 x | 1.96 x |
| Nbr of stocks (in thousands) | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 |
| Reference price 2 | 6.000 | 5.260 | 5.620 | 8.680 | 6.220 | 5.870 |
| Announcement Date | 19-04-28 | 20-04-27 | 21-04-23 | 22-04-06 | 23-04-24 | 24-04-28 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 882.7 | 1,008 | 921.6 | 836.6 | 535.7 | 739.6 |
| EBITDA 1 | 91.09 | 64.04 | 116.1 | 32.54 | -97.08 | 143.9 |
| EBIT 1 | 35.54 | 2.787 | 66.94 | -5.366 | -146.7 | 66.49 |
| Operating Margin | 4.03% | 0.28% | 7.26% | -0.64% | -27.37% | 8.99% |
| Earnings before Tax (EBT) 1 | 34.14 | -18.29 | 28.76 | 20.35 | -221.5 | 23.45 |
| Net income 1 | 13.37 | -26.46 | 9.339 | 10.99 | -187.6 | 11.53 |
| Net margin | 1.51% | -2.62% | 1.01% | 1.31% | -35.01% | 1.56% |
| EPS 2 | 0.0297 | -0.0588 | 0.0208 | 0.0244 | -0.4169 | 0.0256 |
| Free Cash Flow 1 | -177.5 | 214.6 | -345.9 | -236.8 | -18.76 | -130.8 |
| FCF margin | -20.11% | 21.28% | -37.53% | -28.31% | -3.5% | -17.68% |
| FCF Conversion (EBITDA) | - | 335.12% | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1500 | - | 0.0200 | - | - | - |
| Announcement Date | 19-04-28 | 20-04-27 | 21-04-23 | 22-04-06 | 23-04-24 | 24-04-28 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 52.8 | 389 | 334 | 313 | 357 |
| Net Cash position 1 | 152 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.8242 x | 3.356 x | 10.26 x | -3.224 x | 2.482 x |
| Free Cash Flow 1 | -177 | 215 | -346 | -237 | -18.8 | -131 |
| ROE (net income / shareholders' equity) | 1.18% | -1.84% | 1.25% | 0.67% | -13.6% | 0.38% |
| ROA (Net income/ Total Assets) | 0.97% | 0.08% | 1.74% | -0.13% | -3.86% | 1.87% |
| Assets 1 | 1,376 | -33,245 | 536.6 | -8,311 | 4,858 | 617.9 |
| Book Value Per Share 2 | 3.430 | 3.330 | 3.340 | 3.340 | 2.920 | 2.990 |
| Cash Flow per Share 2 | 0.1900 | 0.3700 | 0.5800 | 0.5800 | 0.6000 | 0.3200 |
| Capex 1 | 292 | 131 | 300 | 220 | 58.9 | 138 |
| Capex / Sales | 33.04% | 12.99% | 32.5% | 26.29% | 10.99% | 18.6% |
| Announcement Date | 19-04-28 | 20-04-27 | 21-04-23 | 22-04-06 | 23-04-24 | 24-04-28 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -17.89% | 300M | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- 300086 Stock
- Financials Honz Pharmaceutical Co., Ltd.